Chloprime T 50 Tablet contains Chlorpromazine 50 mg and Trihexyphenidyl 2 mg, a combination formulation used in the management of various psychiatric disorders under medical supervision. The medicine combines the antipsychotic effects of Chlorpromazine with the anticholinergic properties of Trihexyphenidyl to provide comprehensive therapeutic support. This combination is designed to help manage psychiatric symptoms while reducing the risk of certain movement-related side effects associated with antipsychotic therapy.

Chlorpromazine belongs to the phenothiazine class of antipsychotic medicines and works by affecting neurotransmitter activity within the brain, particularly dopamine pathways involved in mood, behavior, and perception. Trihexyphenidyl helps control extrapyramidal symptoms such as muscle stiffness, tremors, and involuntary movements that may occur during antipsychotic treatment. Together, the two ingredients contribute to improved treatment tolerability and patient comfort during long-term therapy.

The tablet is commonly prescribed for schizophrenia, psychotic disorders, severe behavioral disturbances, and other psychiatric conditions as determined by a healthcare professional. By helping manage symptoms such as hallucinations, agitation, disorganized thinking, and behavioral disturbances, the medicine supports overall psychiatric care and patient well-being. Treatment should be individualized according to the patient's condition, clinical response, and medical requirements.

With the growing focus on mental health care and the increasing need for effective psychiatric therapies, Chloprime T 50 Tablet continues to maintain relevance in the neuropsychiatry segment. Its established therapeutic role, physician confidence, and utility in comprehensive psychiatric management contribute to consistent market demand. The product offers valuable business opportunities and long-term growth potential for retailers and distributors operating within the psychiatric pharmaceutical sector.

Chloprime T 50 Tablet may cause drowsiness, dizziness, dry mouth, constipation, blurred vision, low blood pressure, weight changes, tremors, or difficulty concentrating. Some individuals may experience movement disorders, mood changes, or other serious adverse effects requiring medical attention.

Chloprime T 50 Tablet is indicated for schizophrenia, psychotic disorders, severe behavioral disturbances, and other psychiatric conditions as advised by a healthcare professional. It also helps manage extrapyramidal symptoms associated with antipsychotic therapy.

This medication should be used only under the supervision of a qualified healthcare professional. Patients should avoid alcohol and activities requiring mental alertness until they understand how the medicine affects them. Regular medical follow-up may be required during treatment. The medicine should not be discontinued abruptly without consulting a healthcare professional.

Store in a cool, dry place below 25°C, protected from moisture and direct sunlight. Keep the tablets in their original packaging and out of reach of children. Do not use after the expiry date or if the packaging is damaged, opened, or shows signs of tampering.